Ticker

Scienture (NASDAQ: SCNX - Get Free Report) is anticipated to announce its results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Scienture Stock Down 3.1% Shares of NASDAQ: SCNX opened at $0.45 on Tuesday. The business's 50 day moving average is $0.46 and

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers

Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million

Scienture Holdings, Inc. (NASDAQ: SCNX - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totaling 3,504,653 shares, an increase of 46.2% from the December 31st total of 2,397,102 shares. Currently, 11.0% of the company's stock are sold short. Based on an average trading volume

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that…